MSH6 or mutS homolog 6 is a gene that codes for DNA mismatch repair protein Msh6 in the budding yeast Saccharomyces cerevisiae. It is the homologue of the human "G/T binding protein," (GTBP) also called p160 or hMSH6 (human MSH6).

Jul 15, 2023 · This information explains how having a mutation in the MSH6 gene may affect you and your family.

Mar 24, 2025 · MSH6 inherited mutations (Lynch Syndrome) may affect your options for cancer prevention, detection and treatment. FORCE is here to guide you.

The MSH6 gene provides instructions for making a protein that plays an essential role in repairing DNA. This protein helps fix errors that are made when DNA is copied (DNA replication) in preparation for cell division.

MSH6 is a type of tumor suppressor gene known as a DNA mismatch repair gene. When working correctly, tumor suppressor genes help to prevent cancer by controlling the growth and division of cells. • People born with an MSH6 pathogenic variant have only one working copy of the MSH6 gene, so their risk for cancer is higher than average.

Mar 24, 2025 · MSH6 mutations increase the risk for colorectal, endometrial and other types of cancer listed in the table below. Experts at the National Comprehensive Cancer Network (NCCN) created guidelines which estimate the cancer risks for people with MSH6 mutations.

Mar 30, 2025 · MSH6 (MutS Homolog 6) is a Protein Coding gene. Diseases associated with MSH6 include Lynch Syndrome 5 and Endometrial Cancer. Among its related pathways are DNA repair pathways, full network and Base excision repair. Gene Ontology (GO) annotations related to this gene include protein homodimerization activity and ATP hydrolysis activity.

People with an MSH6 mutation who have been diagnosed with cancer may benefit from biomarker testing and may qualify for clinical trials looking for more effective treatments for cancer. The following are examples of situations where an MSH6 mutation may play a part in treatment decision-making.

Here, we briefly describe the disorders that are related to MMR deficiency, as well as the structure and function of MSH6. Moreover, we review the functional assays that are used to examine VUS identified in MSH6 and discuss the results obtained in …

The Msh6-S cyclin fusion was proficient for suppressing mutations at 3 loci that replicate at mid-S phase, whereas the Msh6-G2/M cyclin fusion was defective. However, the Msh6-G2/M cyclin fusion was functional for mismatch repair at a very late-replicating region of the genome.